Long-Term Response Rates to Infliximab Therapy for Crohn’s Disease in an Outpatient Cohort
BACKGROUND: Infliximab’s efficacy in the induction and maintenance of remission in luminal Crohn’s disease has been confirmed by randomized, controlled trials. Less clearly described are long-term outcomes in the clinical practice setting since the establishment of regularly scheduled, every eight-w...
Saved in:
| Main Authors: | Christopher W Teshima, Adrienne Thompson, LeRose Dhanoa, Levinus A Dieleman, Richard N Fedorak |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2009-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/2009/180840 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Study Investigating the Association of Dermatological and Infusion Reactions to Infliximab and Infliximab Trough Levels
by: Vivian Wai-Mei Huang, et al.
Published: (2015-01-01) -
Infliximab in the Treatment of Crohn’s Disease
by: Brian Feagan
Published: (2000-01-01) -
Clinical Experience with Infliximab for Crohn’s Disease: The First 100 Patients in Edmonton, Alberta
by: Clifford Sample, et al.
Published: (2002-01-01) -
Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab.
by: Dario Sorrentino, et al.
Published: (2015-01-01) -
Living with Inflammatory Bowel Disease: A Crohn’s and Colitis Canada Survey
by: Helen M Becker, et al.
Published: (2015-01-01)